S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
Log in

Mylan Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 01/15/2021)
Today's Range
Now: $15.86
50-Day Range
MA: $15.57
52-Week Range
Now: $15.86
Volume14.10 million shs
Average Volume6.49 million shs
Market Capitalization$8.59 billion
P/E Ratio29.92
Dividend YieldN/A
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Mylan logo


Overall MarketRank

1.89 out of 5 stars

Medical Sector

89th out of 1,928 stocks

Pharmaceutical Preparations Industry

40th out of 774 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MYL



Sales & Book Value

Annual Sales$11.50 billion
Cash Flow$8.76 per share
Book Value$23.02 per share


Net Income$16.80 million


Market Cap$8.59 billion
Next Earnings Date2/25/2021 (Estimated)

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mylan (NASDAQ:MYL) Frequently Asked Questions

Is Mylan a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Mylan stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYL, but not buy additional shares or sell existing shares.
View analyst ratings for Mylan
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Mylan?

Wall Street analysts have given Mylan a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mylan wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Mylan

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) announced its quarterly earnings results on Friday, November, 6th. The company reported $1.31 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.16 by $0.15. The firm earned $2.97 billion during the quarter, compared to analyst estimates of $3 billion. Mylan had a net margin of 2.35% and a return on equity of 20.43%. The firm's revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.17 EPS.
View Mylan's earnings history

What price target have analysts set for MYL?

7 brokerages have issued 1-year price objectives for Mylan's stock. Their forecasts range from $16.00 to $27.00. On average, they anticipate Mylan's share price to reach $20.33 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Mylan
or view Wall Street analyst' top-rated stocks.

Who are some of Mylan's key competitors?

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Starbucks (SBUX) and General Electric (GE).

Who are Mylan's key executives?

Mylan's management team includes the following people:
  • Mr. Robert J. Coury, Exec. Chairman (Age 59, Pay $1.83M)
  • Ms. Heather Bresch, CEO & Exec. Director (Age 51, Pay $5.64M)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 59, Pay $4.47M)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 47, Pay $2.55M)
  • Mr. Paul B. Campbell, Chief Accounting Officer, Sr. VP & Corp. Controller
  • Ms. Melissa Trombetta, Head of Global Investor Relations
  • Mr. Dennis Zeleny, Chief Human Relations Officer (Age 65)
  • Ms. Deborah Autor, Sr. VP, Head of Strategic Global Quality & Regulatory Policy
  • Mr. Bill Szablewski, Head of Capital Markets
  • Mr. Joseph F. Haggerty, Corp. Sec.

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $15.86.

How big of a company is Mylan?

Mylan has a market capitalization of $8.59 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is www.mylan.com.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.